Access to Data and Information. The Institute will timely provide the School with access to any data and information pertaining to the School that it receives from the State or other sources including but not limited to test scores, Exceptional Student Education Act data, school improvement status, accreditation, special education, and funding information.
Access to Data and Information. The District will timely provide the School with access to any data and information pertaining to the School that it receives from the State or other sources including but not limited to test scores, Every Student Succeeds Act (ESSA) school improvement status, SPF, accreditation, special education, and funding information.
Access to Data and Information. The Sponsor shall timely provide the School with access to any data and information pertaining to the School that it receives from the State or other sources, including but not limited to test scores, federal and state accountability data, special education data, student enrollment data, and funding information.
Access to Data and Information. Any Party which does not participate in sole risk operations carried out under Section 8.2 (a) shall not be entitled to have access to any data or information obtained in respect of such sole risk operations, provided that any Non Sole Risk Participant may at any time become entitled to have access to and shall become a joint owner of such data and information obtained from such sole risk operations upon payment in cash to the Sole Risk Participants of an amount equal to………per cent (. %) of the amount it would have contributed to the Joint Account if such operations had been carried out as part of the Joint Operations.
Access to Data and Information. Sepracor shall own and have the right to access free of charge all information and data generated in all Development activities and all pre-clinical, clinical and marketing studies with respect to the Products.
Access to Data and Information. (a) Each Party shall have the right to access and use all Agreement Confidential Information generated in all clinical and marketing studies with respect to the Agreement Product for the purposes of this Agreement. Subject to the terms and conditions of this Agreement, Sequus shall have access to all Agreement Confidential Information derived from clinical trials on a timely basis and be entitled to use such Agreement Confidential Information only for registration, promoting, distributing, marketing and selling the Agreement Product and the providing of such Agreement Confidential Information to any Regulatory Authority or to any third party distributing, marketing or selling Agreement Product. Subject to the terms and conditions of this Agreement, Schering shall have access to the Know-how, Trademarks and Sequus Confidential Information to enable Schering to distribute, market and sell the Agreement Product in the Territory for all uses not disallowed under applicable law.
(b) Each party shall have the right of cross-reference to the other party's regulatory filings (e.g., IND, NDA, CTX, etc.). Schering shall have the right to participate with Sequus in all contacts with the FDA regarding the clinical development, toxicology and chemistry, manufacturing, controls ("CMC") issues relating to the Agreement Product.** Schering shall have full access to all correspondence with the FDA or other Regulatory Authorities relating to the Agreement Product. Notwithstanding the foregoing rights of access, participation and limits on use, Sequus shall own the Sequus Confidential Information and Schering shall own the Schering Confidential Information.
(c) Sequus may not provide Agreement Confidential Information generated by Schering to a third party to distribute, market and sell Agreement Product ** unless Sequus obtains a reciprocal right on Schering's behalf to obtain from such third party the right for Schering to use information and data generated by such third party to distribute, market and sell Agreement Product in the Territory. **
(d) If Sequus provides Agreement Confidential Information generated by Schering to a third party to distribute, market and sell Agreement Product ** Sequus shall obtain a reciprocal right on Schering's behalf to obtain from such third party the right for Schering to use information and data generated by such third party to distribute, market and sell Agreement Product in the Territory. **
(e) Nothing provided herein shall prohibit ...
Access to Data and Information. AGE shall own and have the right to access free of charge all information and data generated in all Development activities and all laboratory testing and studies with respect to the Products, including but not limited to the University Testing of the Products and Pilot Phase of Development.
Access to Data and Information. Evolent hereby acknowledges and agrees that UPMC has fulfilled all commitments and obligations to provide any UPMC case studies, collateral, health system operating procedures, training manuals, certain data and other information as referenced in the Original UPMC Reseller Agreement and the First Amended and Restated Reseller Agreement, and that UPMC shall have no further obligation to provide any further data or information after the Effective Date of this Agreement. All requests for access to such Data and Information shall be on terms to be agreed upon between the Parties in separate SOW.
Access to Data and Information. Subject to the provisions of this Agreement, each Party shall have the right to access and use all information generated in all clinical and marketing studies with respect to the Product in the Field for sale in the Territory (VF) or outside the Field or the Territory (OPKO); provided, however, if either Party wishes to access and use new data generated by the other Party, its Affiliates, or its licensees/sublicensees that is not in the public domain, [***]. Notwithstanding the foregoing, each Party acknowledges and agrees that it will share all safety data, information and results required to ensure compliance by each Party with Applicable Law and safety standards at no cost to the other Party and that OPKO will make available to VF any additional information and content developed or acquired by OPKO that is required for the registration process in the Territory.
Access to Data and Information. Subject to the provisions of this Agreement, each Party shall have upon reasonable request the right to access (which shall include, but not be limited to, the right to make photocopies) and, with respect to Merck within the Territory and with respect to Kos anywhere in the world, use **** all information and data generated in all clinical and marketing studies with respect to the Products. Notwithstanding the foregoing, neither Party shall be obligated to provide the other Party with access to any information to the extent prohibited by law, including without limitation signed informed consents for study participants.
